T-Therapeutics Announces Oversubscribed $133 Million Series B Financing
T-Therapeutics says the financing will support clinical proof-of-concept for its TCR bispecific therapies in cancer and autoimmune disease.
Related stories
Spago Nanomedical Q3 loss narrows 30% to SEK 4.38 million
M impact | EQUITY | Nov 05, 2026, 07:21 AM UTC
Orsted Reports Third-Quarter Net Profit of DKK963 Million
M impact | EQUITY | Nov 05, 2026, 07:07 AM UTC
Wästbygg Reports Q3 Revenue of SEK 621 Million
M impact | EQUITY | Nov 05, 2026, 07:07 AM UTC
Chant Sincere Reports Third-Quarter Net Profit of NT$71.8M
Chant Sincere reported third-quarter net profit of NT$71.8 million, compared with NT$50.9 million a year earlier. Revenue was NT$393.017 million versus NT$334.726 million, and pret
M impact | EQUITY | Nov 05, 2026, 07:06 AM UTC
Eesti Energia Plans 10% Position Reduction, Begins Consultations
Eesti Energia Group plans to reduce total positions by 10% and begin preliminary consultations on collective redundancies. The proposed process includes 390 positions across Enefit
L impact | EQUITY | Nov 05, 2026, 07:06 AM UTC
OSB Group Launches Tender Offers for Up to £500 Million of Notes
OSB Group launched cash tender offers for up to £500 million of notes.
M impact | EQUITY | Nov 05, 2026, 07:05 AM UTC